Cargando…

What FXYDs fix

Na,K ATPases are modulated by FXYD subunits. What do the FXYDs affect, how do they do it, and what are their physiological impacts?

Detalles Bibliográficos
Autores principales:	Habeck, Michael, Poulsen, Hanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059070/ https://www.ncbi.nlm.nih.gov/pubmed/33871566 http://dx.doi.org/10.1085/jgp.202012845

Ejemplares similares

Impaired AQP2 trafficking in Fxyd1 knockout mice: A role for FXYD1 in regulated vesicular transport
por: Arystarkhova, Elena, et al.
Publicado: (2017)

Displacement of Native FXYD Protein From Na(+)/K(+)-ATPase With Novel FXYD Peptide Derivatives: Effects on Doxorubicin Cytotoxicity
por: Liu, Chia-Chi, et al.
Publicado: (2022)

FXYD proteins and sodium pump regulatory mechanisms
por: Yap, John Q., et al.
Publicado: (2021)

FXYD6 is a new biomarker of cholangiocarcinoma
por: CHEN, XIONGFEI, et al.
Publicado: (2014)

Commentary: You cannot fix what you cannot see
por: Cook, Chris C., et al.
Publicado: (2020)

FXYD3: A Promising Biomarker for Urothelial Carcinoma
por: Zhang, ZhongFa, et al.
Publicado: (2011)

Expression and clinical significance of FXYD3 in endometrial cancer
por: LI, YIFEI, et al.
Publicado: (2014)

Expression and Significance of FXYD-3 Protein in Gastric Adenocarcinoma
por: Zhu, Zhen-Long, et al.
Publicado: (2010)

FXYD6 promotes thermal nociception by regulating TRPV1
por: Luo, Hao, et al.
Publicado: (2021)

FXYD-3 expression in relation to local recurrence of rectal cancer
por: Loftas, Per, et al.
Publicado: (2016)

FXYD5: Na(+)/K(+)-ATPase Regulator in Health and Disease
por: Lubarski Gotliv, Irina
Publicado: (2016)

FXYD6 overexpression in HBV-related hepatocellular carcinoma with cirrhosis
por: Chen, Xiongfei, et al.
Publicado: (2020)

Physician Burnout: Fix the Doctor or Fix the System?
por: Greep, Nancy C., et al.
Publicado: (2022)

Expression mode and prognostic value of FXYD family members in colon cancer
por: Jin, Ming, et al.
Publicado: (2021)

FXYD6: a novel therapeutic target toward hepatocellular carcinoma
por: Gao, Qian, et al.
Publicado: (2014)

FXYD5 Is an Essential Mediator of the Inflammatory Response during Lung Injury
por: Brazee, Patricia L., et al.
Publicado: (2017)

Epigenetic remodelling of Fxyd1 promoters in developing heart and brain tissues
por: Cuomo, Mariella, et al.
Publicado: (2022)

Overexpression of FXYD-3 Is Involved in the Tumorigenesis and Development of Esophageal Squamous Cell Carcinoma
por: Zhu, Zhen-Long, et al.
Publicado: (2013)

Renal Mg handling, FXYD2 and the central role of the Na,K‐ATPase
por: Mayan, Haim, et al.
Publicado: (2018)

FXYD protein isoforms differentially modulate human Na/K pump function
por: Meyer, Dylan J., et al.
Publicado: (2020)

Effect of differentiation, de novo innervation, and electrical pulse stimulation on mRNA and protein expression of Na(+),K(+)-ATPase, FXYD1, and FXYD5 in cultured human skeletal muscle cells
por: Jan, Vid, et al.
Publicado: (2021)

Commentary: Fixing the hole
por: Glower, Donald D.
Publicado: (2020)

Prognostic significance of sodium-potassium ATPase regulator, FXYD3, in human hepatocellular carcinoma
por: Wang, Li-Juan, et al.
Publicado: (2018)

Can complement fix placental malaria?
por: Doritchamou, Justin Y. A., et al.
Publicado: (2021)

Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
por: Vallois, David, et al.
Publicado: (2014)

FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas
por: Raman, Pichai, et al.
Publicado: (2015)

Fxyd2 regulates Aδ- and C-fiber mechanosensitivity and is required for the maintenance of neuropathic pain
por: Ventéo, Stéphanie, et al.
Publicado: (2016)

FXYD3 Expression Predicts Poor Prognosis in Renal Cell Carcinoma with Immunosuppressive Tumor Microenvironment
por: Yonekura, Satoru, et al.
Publicado: (2022)

Time-Dependent Exposures and the Fixed-Cohort Bias
por: Barnett, Adrian G.
Publicado: (2011)

Fixing the leak: targeting the vascular endothelium in sepsis
por: Spicer, Aaron, et al.
Publicado: (2012)

FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway
por: Ding, Licheng, et al.
Publicado: (2022)

Correction: Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
Publicado: (2014)

Missense variants in ATP1A3 and FXYD gene family are associated with childhood-onset schizophrenia
por: Chaumette, Boris, et al.
Publicado: (2018)

Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma
por: Hsu, I-Ling, et al.
Publicado: (2016)

FXYD8, a Novel Regulator of Renal Na(+)/K(+)-ATPase in the Euryhaline Teleost, Tetraodon nigroviridis
por: Wang, Pei-Jen, et al.
Publicado: (2017)

Fxyd5 activates the NF-κB pathway and is involved in chondrocytes inflammation and extracellular matrix degradation
por: Song, Lulu, et al.
Publicado: (2022)

FXYD2 antisense oligonucleotide provides an efficient approach for long-lasting relief of chronic peripheral pain
por: Derre, Alexandre, et al.
Publicado: (2023)

Fixing DNA breaks during class switch recombination
por: Jolly, Christopher J., et al.
Publicado: (2008)

The US war on harm reduction: fixing policy on intelligence and facts
por: Wodak, Alex
Publicado: (2005)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hhvnqoqmrbor3sbpvvs1phvolj